These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20881844)

  • 21. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies.
    Vieta E; Mullen J; Brecher M; Paulsson B; Jones M
    Curr Med Res Opin; 2005 Jun; 21(6):923-34. PubMed ID: 15969892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.
    Katzman MA; Brawman-Mintzer O; Reyes EB; Olausson B; Liu S; Eriksson H
    Int Clin Psychopharmacol; 2011 Jan; 26(1):11-24. PubMed ID: 20881846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone.
    Canuso CM; Grinspan A; Kalali A; Damaraju CV; Merriman U; Alphs L; Awad AG
    Int Clin Psychopharmacol; 2010 May; 25(3):155-64. PubMed ID: 20216424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study.
    Schmauss M; Jukić V; Siracusano A; Bidzan L; Badescu GM; Maciulis V; Lahaye M; Hoeben D; Tessier C; Schreiner A
    Curr Med Res Opin; 2012 Aug; 28(8):1395-404. PubMed ID: 22746355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease.
    Amatniek J; Canuso CM; Deutsch SI; Henderson DC; Mao L; Mikesell C; Rodriguez S; Sheehan J; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Apr; 8(1):8-20. PubMed ID: 23428785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    Buckley PF
    Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled study.
    Peuskens J; Trivedi JK; Brecher M; Miller F;
    Int Clin Psychopharmacol; 2010 May; 25(3):183-7. PubMed ID: 20216222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
    Owen RT
    Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
    Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR;
    J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.
    Pandina GJ; Lindenmayer JP; Lull J; Lim P; Gopal S; Herben V; Kusumakar V; Yuen E; Palumbo J
    J Clin Psychopharmacol; 2010 Jun; 30(3):235-44. PubMed ID: 20473057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release.
    Boom S; Talluri K; Janssens L; Remmerie B; De Meulder M; Rossenu S; van Osselaer N; Eerdekens M; Cleton A
    J Clin Pharmacol; 2009 Nov; 49(11):1318-30. PubMed ID: 19713555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study.
    Berwaerts J; Xu H; Nuamah I; Lim P; Hough D
    J Affect Disord; 2012 Jan; 136(1-2):e51-e60. PubMed ID: 20624657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
    Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies.
    Meulien D; Huizar K; Brecher M
    Hum Psychopharmacol; 2010 Mar; 25(2):103-15. PubMed ID: 20196185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paliperidone extended release: a review of its use in the management of schizophrenia.
    Chwieduk CM; Keating GM
    Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.
    Figueroa C; Brecher M; Hamer-Maansson JE; Winter H
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):199-204. PubMed ID: 18948162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.
    Vieta E; Calabrese JR; Goikolea JM; Raines S; Macfadden W;
    Bipolar Disord; 2007 Jun; 9(4):413-25. PubMed ID: 17547587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paliperidone: a review of clinical trial data and clinical implications.
    Wang SM; Han C; Lee SJ; Patkar AA; Pae CU; Fleischhacker WW
    Clin Drug Investig; 2012 Aug; 32(8):497-512. PubMed ID: 22747259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER.
    Knapp M; Locklear J; Järbrink K
    Curr Med Res Opin; 2009 Jul; 25(7):1593-603. PubMed ID: 19469696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.